Clinical trials located in

Wuppertal

Wuppertal city is located in Germany. Currently, 13 clinical trials are being conducted in this city.

Wuppertal, nestled in Germany’s Bergisches Land region, is renowned for its unique suspension railway, the Schwebebahn, operational since 1901. This engineering marvel traverses the city, offering a distinctive mode of urban transport. Wuppertal is also the birthplace of famed dance choreographer Pina Bausch, contributing significantly to the global arts scene. The city’s lush, green valleys and historical architecture, including the historic town hall and the Von der Heydt Museum, rich in art collections, underscore its cultural and historical significance.

  • CT-EU-00057838

    Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    BelgiumGermanyPolandSpain
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Study on digital health’s effect on cancer treatment success

    This research is checking out how the use of digital health solutions (like apps and online platforms) can affect patients. The patients in focus here are those who are receiving systemic treatment, which is used to treat cancer. The aim is to see if using digital health solutions can enhance the health of patients, using fewer health-care resources like hospital visits. Additionally, the study will consider patients who are on approved anti-cancer treatment plans, and also those who may be on treatments not officially approved.

    AustriaGermanySpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Apalutamide treatment for advanced prostate cancer post-surgery

    This clinical trial is looking into a treatment that could help people with a high risk of prostate cancer that could spread to other body parts after surgery. The treatment being studied is called apalutamide. The researchers want to see if this apalutamide can help stop the cancer from returning and spreading after surgery, compared to the standard care that these patients get. The trial will measure the amount of time until the cancer comes back, it has spread to other parts, or a patient dies from any cause. If there’s an increase in PSA (it is a protein made by normal cells and prostate cancer cells), the disease might have come back. The trial will also look at whether and how fast the PSA levels increase after recurrence. If there are no such events until the end of the observation period, the patient’s observation will end on the date of their last contact. The trial also looks at how safe this treatment is and what side effects it may cause.

    AustriaGermany
  • Comparing new drug-Cytarabine Danuorubicin with standard chemotheraphy in adults with Acute Myeloid Leukemia

    This study is comparing two types of strong medicine, or ‘chemotherapy’, used to treat a disease called Acute Myeloid Leukemia (AML). This disease can sometimes be harder to treat in some patients due to their genetics. In this study, some people will get the usual strong medicine, and some people will get a new type of strong medicine called CPX-351 (Cytarabine and Danuorubicin). The researchers will also look at who might get fully or almost fully better from the disease.This trial is investigating how a new kind of very strong drug, CPX-351, might work compared to the usual strong drug treatment for a blood cancer called Acute Myeloid Leukemia (AML). These drugs are used when someone has recently found out they have AML, and their body has certain genetic markers making it harder for usual treatments to work. This trial is also looking at different degrees of recovery. The treatments may work differently based on people’s genes.

    AustriaGermany
  • Belimumab study for systemic sclerosis-lung disease

    This study evaluates belimumab’s efficacy and safety compared to a placebo in treating systemic sclerosis-associated interstitial lung disease (SSc-ILD). Approximately 300 participants will receive belimumab or a placebo alongside standard therapy. The main focus is on the drug’s impact on lung function, skin thickening, and symptoms affecting quality of life, like fatigue. The study aims to provide insights into better managing SSc-ILD, improving patient outcomes.

    BelgiumDenmarkFinlandFranceGermanyGreeceItalySpainUnited Kingdom
  • Breast cancer treatment study: camizestrant vs. standard therapy

    This study is looking at a new drug called camizestrant for adults with a certain type of early breast cancer (ER+/HER2-). It compares camizestrant with standard endocrine therapies like tamoxifen and aromatase inhibitors in patients who have already received 2–5 years of endocrine therapy. The study’s focus is on preventing cancer recurrence over 60 months. About 4300 participants are involved, and the trial features an open-label design, meaning everyone knows which treatment they are receiving. The main goal is to check how well the camizestrant works in comparison to standard treatments.

    AustriaBelgiumBulgariaCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandPortugalRomaniaSpainUnited Kingdom
  • Study of Dato-DXd and durvalumab in persistent triple-negative breast cancer

    This trial is about testing a combination of new treatments for triple-negative breast cancer which hasn’t fully responded to the first line of treatment. The new treatment includes a drug called Dato-DXd and a known drug called Durvalumab, both administered individually, or as a combination. This is compared to an already established treatment recommended by the doctor. The researchers are mainly interested in delaying the return of the cancer, and if the new drug with or without Durvalumab does a better job at this than the doctor-recommended treatment. Along with this main goal, the trial will also monitor how these treatments affect patients’ routine activities, their well-being, their levels of fatigue, the amount of Dato-DXd and related components present in the body, and any side effects and potential risks associated with these treatments.

    BelgiumDenmarkFranceGermanyGreeceItalySpainSwedenUnited Kingdom
  • Long-term safety & effectiveness of rocatinlimab for atopic dermatitis

    This trial is all about studying a medicine called rocatinlimab for grown-ups and teens with a serious skin disease named atopic dermatitis (AD). The main goal is to see if rocatinlimab is safe and can help over a long period. The research will also check how well people tolerate the medication. The focus is on those who previously benefitted from the medicine, showing an improvement on a scoring system that measures itching levels. This trial falls in the third phase, making it crucial towards verifying the effectiveness and monitoring any adverse effects of the drug.

    AustriaCzechiaDenmarkFranceGermanyGreeceHungaryPolandPortugalSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Germany:

.